Status:
COMPLETED
A Study of Experimental Medication BMS-986235 in Healthy Subjects
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Mediators of Inflammation
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a study of experimental medication BMS-986235 in healthy subjects.
Eligibility Criteria
Inclusion
- Patients must be normal healthy volunteers as determined by no clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations
- Patients must have a body mass index (BMI) of 18 - 30 mg/kg2, inclusive
Exclusion
- Patients that are pregnant
- Patient with any significant acute or chronic medical illness
- Patient with a current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption
- Patient with any surgery within 12 weeks of study treatment administration
- Patient with any gastrointestinal surgery that could impact upon the absorption of study drug
- Patient who donated blood to a blood bank or in a clinical study (except a screening visit) within 12 weeks of study drug administration (within 2 weeks for plasma only)
- Patient who received a blood transfusion within 12 weeks of study drug administration
- Other protocol defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
November 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2021
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT03335553
Start Date
November 15 2017
End Date
July 2 2021
Last Update
March 31 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim Clinical Trials
Anaheim, California, United States, 92801
2
PRA Health Sciences
Salt Lake City, Utah, United States, 84107